NDC product
Bisoprolol Fumarate and Hydrochlorothiazide
NDC 10135-741 · Marlex Pharmaceuticals, Inc.
Key facts
| Product NDC | 10135-741 |
|---|---|
| Proprietary name | Bisoprolol Fumarate and Hydrochlorothiazide |
| Nonproprietary name | Bisoprolol Fumarate and Hydrochlorothiazide |
| Substances | BISOPROLOL FUMARATE, HYDROCHLOROTHIAZIDE |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Marlex Pharmaceuticals, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA215562 |
| Pharmacologic classes | Adrenergic beta-Antagonists [MoA], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS], beta-Adrenergic Blocker [EPC] |
| Marketing start | May 1, 2022 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: